Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT07211997Recruiting

FebriDx® Pediatric Validation Study

Role: lead

NCT05998109Completed

PheCheck Feasibility Study

Role: lead

NCT06746259Completed

FebriDx® Method Comparison Study Protocol

Role: lead

NCT05403346Terminated

Clinical Evaluation of a COVID-19 Antigen Self-Test (CoviDx™)

Role: lead

NCT04750629Completed

Clinical Evaluation of a Point-of-Care (POC), COVID-19 Rapid Antigen Test (CoviDx™)

Role: lead

NCT04699903Completed

Clinical Evaluation of a Point-of-Care (POC), SARS-CoV-2 (COVID-19) IgG Antibody Test in Fingerstick Whole Blood

Role: lead

All 6 trials loaded